ATE546143T1 - Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen - Google Patents

Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen

Info

Publication number
ATE546143T1
ATE546143T1 AT03791404T AT03791404T ATE546143T1 AT E546143 T1 ATE546143 T1 AT E546143T1 AT 03791404 T AT03791404 T AT 03791404T AT 03791404 T AT03791404 T AT 03791404T AT E546143 T1 ATE546143 T1 AT E546143T1
Authority
AT
Austria
Prior art keywords
prostaglandins
kinase inhibitor
rho
agent
treating glaucoma
Prior art date
Application number
AT03791404T
Other languages
English (en)
Inventor
Tadashi Nakajima
Takeshi Matsugi
Hideaki Hara
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE546143T1 publication Critical patent/ATE546143T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT03791404T 2002-08-29 2003-08-29 Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen ATE546143T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002250223 2002-08-29
PCT/JP2003/011004 WO2004019951A1 (ja) 2002-08-29 2003-08-29 Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤

Publications (1)

Publication Number Publication Date
ATE546143T1 true ATE546143T1 (de) 2012-03-15

Family

ID=31972618

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03791404T ATE546143T1 (de) 2002-08-29 2003-08-29 Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen

Country Status (11)

Country Link
US (4) US20050245509A1 (de)
EP (2) EP1541151B1 (de)
JP (1) JP5174777B2 (de)
KR (2) KR101092048B1 (de)
CN (1) CN100425241C (de)
AT (1) ATE546143T1 (de)
AU (1) AU2003257588A1 (de)
CA (1) CA2496797C (de)
ES (1) ES2382733T3 (de)
TW (2) TWI350170B (de)
WO (1) WO2004019951A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI350170B (en) * 2002-08-29 2011-10-11 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
WO2004045644A1 (ja) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
KR101333970B1 (ko) * 2005-05-19 2013-11-27 코와 가부시키가이샤 녹내장 예방 또는 치료제
US8629161B2 (en) * 2005-06-21 2014-01-14 Kowa Co., Ltd. Preventive or remedy for glaucoma
PT1905452E (pt) * 2005-07-12 2013-07-16 Kowa Co Agente para a prevenção ou tratamento do glaucoma
KR101149954B1 (ko) * 2005-08-30 2012-06-01 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물
US7893050B2 (en) 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
CA2664335C (en) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
EP2130828A4 (de) 2007-02-28 2010-12-29 Asahi Kasei Pharma Corp Sulfonamidderivat
CN101313926B (zh) * 2007-05-30 2012-12-26 中央研究院 转录调控物组合物
ES2396795T3 (es) 2007-07-02 2013-02-27 Asahi Kasei Pharma Corporation Compuesto de sulfonamida y cirstal del mismo
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3053913B1 (de) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Hemmer mit doppelmechanismus zur behandlung von erkrankungen
CA2805242A1 (en) * 2010-07-19 2012-01-26 Inspire Pharmaceuticals, Inc. Bifunctional rho kinase inhibitor compounds, composition and use
JP5822840B2 (ja) 2010-09-30 2015-11-24 ダイトーケミックス株式会社 眼疾患処置薬
TW201235040A (en) * 2011-02-04 2012-09-01 Kowa Co Drug therapy for preventing or treating glaucoma
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
WO2014010654A2 (ja) * 2012-07-13 2014-01-16 参天製薬株式会社 スルホンアミド化合物の組み合わせ
CN109528721B (zh) * 2013-03-15 2021-10-01 爱瑞制药公司 联合治疗
KR102307281B1 (ko) 2013-10-31 2021-09-29 알레간 인코포레이티드 프로스타마이드-함유 안구내 삽입물 및 그것의 사용 방법
KR20150090445A (ko) 2014-01-29 2015-08-06 주식회사 이노칩테크놀로지 적층칩 소자
CA2970254A1 (en) * 2014-12-12 2016-06-16 Kowa Company, Ltd. Composition
GB2556500A (en) * 2015-05-29 2018-05-30 Edge Therapeutics Inc Compositions and methods for reducing visual loss
KR102579582B1 (ko) 2015-11-17 2023-09-15 에어리 파마슈티컬즈, 인코포레이티드 키나아제 억제제 및 이의 중간체의 제조 방법
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CA3035566A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
CN111479568A (zh) * 2017-12-21 2020-07-31 参天制药株式会社 司培前列素与Rho激酶抑制剂的组合药物
KR20200103041A (ko) 2017-12-21 2020-09-01 산텐 세이야꾸 가부시키가이샤 오미데네팍의 조합
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
CN108815169A (zh) * 2018-05-23 2018-11-16 中南大学湘雅医院 一种***素类物质组合得到有效的青光眼治疗剂
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2021182596A1 (ja) * 2020-03-13 2021-09-16 興和株式会社 上眼瞼溝深化改善剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945008C2 (de) * 1979-11-08 1981-08-20 Lück, Werner, 4290 Bocholt Stützelement für medizinische Lagerungszwecke
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4952581A (en) * 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
ATE76750T1 (de) 1987-04-03 1992-06-15 Univ Columbia Anwendung eines prostaglandins in mischung mit einem adrenergischen blocker zur verminderung des augen-innendruckes.
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ATE82499T1 (de) 1987-09-18 1992-12-15 R Tech Ueno Ltd Okulare hypotensivagenzien.
CA1334168C (en) * 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
JPH02108U (de) 1988-06-14 1990-01-05
WO1990002553A1 (en) * 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JP3719609B2 (ja) * 1995-12-21 2005-11-24 アルコン ラボラトリーズ，インコーポレイテッド 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用
NZ334613A (en) * 1996-08-12 2002-02-01 Welfide Corp Pharmaceutical agents comprising Rho kinase inhibitor
ES2314786T3 (es) * 1998-04-02 2009-03-16 Genentech, Inc. Uso de interferon gamma para el tratamiento de la hipertrofia cardiaca.
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
ES2372572T3 (es) * 1998-08-17 2012-01-23 Senju Pharmaceutical Co., Ltd. Agente para profilaxis y tratamiento de glaucoma.
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
AU3328600A (en) * 1999-03-25 2000-10-16 Santen Pharmaceutical Co. Ltd. Ocular tension-lowering agents
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AR035541A1 (es) 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
DE60211317T2 (de) 2001-03-23 2007-04-12 Bayer Corp. Rho-kinase inhibitoren
PT1370552E (pt) 2001-03-23 2007-04-30 Bayer Pharmaceuticals Corp Inibidores de rho-quinase
EP1403255A4 (de) 2001-06-12 2005-04-06 Sumitomo Pharma Rho-kinase-inhibitoren
US7015210B2 (en) * 2001-12-12 2006-03-21 Pharmacia Corporation Methods of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
TWI350170B (en) * 2002-08-29 2011-10-11 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
WO2004045644A1 (ja) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy

Also Published As

Publication number Publication date
KR20110004920A (ko) 2011-01-14
KR101092048B1 (ko) 2011-12-12
JP2009298808A (ja) 2009-12-24
US20100041671A1 (en) 2010-02-18
US20120040994A1 (en) 2012-02-16
EP1541151A4 (de) 2007-07-18
CN100425241C (zh) 2008-10-15
WO2004019951A1 (ja) 2004-03-11
CA2496797C (en) 2012-01-10
US20100063060A1 (en) 2010-03-11
EP1541151A1 (de) 2005-06-15
CA2496797A1 (en) 2004-03-11
TWI337881B (en) 2011-03-01
EP2314299A1 (de) 2011-04-27
KR101160780B1 (ko) 2012-06-27
JP5174777B2 (ja) 2013-04-03
TW201032807A (en) 2010-09-16
CN1684689A (zh) 2005-10-19
US20050245509A1 (en) 2005-11-03
TW200409654A (en) 2004-06-16
TWI350170B (en) 2011-10-11
ES2382733T3 (es) 2012-06-13
KR20050057014A (ko) 2005-06-16
EP1541151B1 (de) 2012-02-22
AU2003257588A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
ATE546143T1 (de) Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
EA200801492A1 (ru) Фармацевтическое применение замещенных амидов
ATE482747T1 (de) Neue amide derivate und deren pharmazeutische verwendungen
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
MX2009009623A (es) Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide.
EA200101166A1 (ru) Ингибиторы металлопротеаз
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
DE502004005033D1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
ATE451361T1 (de) Materialien und methoden zur behandlung von koagulationsstörungen
ATE504294T1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
DK1283038T3 (da) Dögnrytmenormaliserende sammensætninger
ATE457729T1 (de) Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie
HUP0400553A2 (hu) Gyógyászati készítmények
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
ATE444069T1 (de) Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
IS6555A (is) Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni
DE69910706D1 (de) Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie